title: Managed ventricular pacing vs. conventional dual-chamber pacing for elective replacements: the PreFER MVP study: clinical background, rationale, and design.
abstract: OBJECTIVE
  Several clinical studies have shown that, in patients with intact atrioventricular (AV) conduction, unnecessary chronic right ventricular (RV) pacing can be detrimental. The managed ventricular pacing (MVP) algorithm is designed to give preference to spontaneous AV conduction, thus minimizing RV pacing. The clinical outcomes of MVP are being studied in several ongoing trials in patients undergoing a first device implantation, but it is unknown to what extent MVP is beneficial in patients with a history of ventricular pacing. The purpose of the Prefer for Elective Replacement MVP (PreFER MVP) study is to assess the superiority of the MVP algorithm to conventional pacemaker and implantable cardioverter-defibrillator programming in terms of freedom from hospitalization for cardiovascular causes in a population of patients exposed to long periods of ventricular pacing.
  
  
  RESULTS
  PreFER MVP is a prospective, 1:1 parallel, randomized (MVP ON/MVP OFF), single-blinded multi-centre trial. The study population consists of patients with more than 40% ventricular pacing documented with their previous device. Approximately, 600 patients will be randomized and followed for at least 24 months. The primary endpoint comprises cardiovascular hospitalization.
  
  
  CONCLUSIONS
  The PreFER MVP trial is the first large prospective randomized clinical trial evaluating the effect of MVP in patients with a history of RV pacing.
authors.affiliation: Department of Cardiology, Hospital General Universitario de Valencia, Avenida Tres Cruces s/n, Valencia 46014, Spain. quesada_aur@gva.es
authors.forename: Aurelio
authors.initials: A
authors.lastname: Quesada
authors.forename: Gianluca
authors.initials: G
authors.lastname: Botto
authors.forename: Ali
authors.initials: A
authors.lastname: Erdogan
authors.forename: Milan
authors.initials: M
authors.lastname: Kozak
authors.forename: Peter
authors.initials: P
authors.lastname: Lercher
authors.forename: Jens Cosedis
authors.initials: JC
authors.lastname: Nielsen
authors.forename: Olivier
authors.initials: O
authors.lastname: Piot
authors.forename: Renato
authors.initials: R
authors.lastname: Ricci
authors.forename: Christian
authors.initials: C
authors.lastname: Weiss
authors.forename: Daniel
authors.initials: D
authors.lastname: Becker
authors.forename: Gwenn
authors.initials: G
authors.lastname: Wetzels
authors.forename: Luc
authors.initials: L
authors.lastname: De Roy
mesh_terms: D000465:Algorithms; D001315:Australia; D002170:Canada; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000628:therapy*; D017147:Defibrillators, Implantable; D005060:Europe; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology; D006352:Heart Ventricles / Q000503:physiopathology*; D006801:Humans; D008877:Middle East; D010138:Pacemaker, Artificial; D011446:Prospective Studies; D016037:Single-Blind Method